Developing a new targeted therapy for treatment of metastic prostate cancer: synthesis and preclinical validation of sphingosine inhibitor-docetaxel combination nanoparticles

Project Details

StatusFinished
Effective start/end date16/09/1331/07/17

Funding

  • Prostate Cancer UK: £249,998.00